DRKS00031301已完成Unknown
Evaluation of an Open-Label Placebo Appetite suppressant - An eye-tracking study
niversität Graz0 个研究点目标入组 53 人开始时间: 2023年3月10日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- Female
入选标准
- •Normal or corrected-to-normal vision at 1m distance
排除标准
- •Medication that may affect eating beavior/appetite.
研究者
相似试验
尚未招募
不适用
Open-label placebo treatment to reduce appetite/overeating in obese children: an app-assisted approachE66.04obesityDRKS00029251niversität Graz80
招募中
不适用
Open-label placebos and eating behaviour. A randomized controlled studyDesire to lose weightDRKS00024101Medical School Berlin100
已完成
不适用
A randomised open label placebo study to evaluate the use of Solcogyn applied topically to the cervix in women referred for the assessment of cervical low grade intro-epithelial lesionsISRCTN06133220Department of Health (UK)106
已完成
4 期
Atosiban (6.75 mg) injection to delay preterm birthCTRI/2017/11/010518Zuventus Healthcare Limited75
终止
不适用
Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer SurvivorsFatigue in Cancer SurvivorsNCT02452710Dana-Farber Cancer Institute40